Epirubicin, cisplatin, oral UFT, and leucovorin combination chemotherapy in advanced and metastatic esophageal cancer

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: The purpose of treatment in patients with advanced and metastatic esophageal cancer is to improve symptoms and maintain quality of life. Recently, the regimen including epirubicin, cisplatin, and 5-FU (ECF) has been used with protracted venous infusion (PVI), and has been reported to be an effective treatment for advanced and metastatic csophagastric cancer. However, complications and the inconvenience associated with PVI cannot be justified for the treatment of advanced esophageal cancer. Therefore, we provided treatment with oral UFT and leucovorin instead of 5-FU PVI to improve convenience and catheter related complications. Patients and Methods: Thirty-seven patients with advanced esophageal cancer were admitted between March 2002 and April 2005. The treatment schedule was as follows: epirubicin 50 mg/m2 iv on d 1, cisplatin 60 mg/m2 iv on d 1, oral UFT 300 mg/m2 and leucovorin 75 mg for 21 consecutive days of treatment followed by a 7-d treatment-free interval. Results: The response rate was 45.9% including one complete response (95% CI: 29.8%-62%). The median survival was 13 mo (95% CI: 10-16 mo). Four patients had adenocarcinoma. Interestingly, their response rate was 75% including one complete response. Myelosuppression was the most important toxicity. Other toxicities were tolerable. Conclusion: The combination of epirubicin, cisplatin, UFT, and leucovorin (EPUL) could be another alternative to ECF in patients with advanced esophageal cancer. And this treatment might be more effective in adenocarcinoma of esophageal cancer.

Original languageEnglish
Pages (from-to)33-37
Number of pages5
JournalMedical Oncology
Volume24
Issue number1
DOIs
Publication statusPublished - 2007 Jun 1

Fingerprint

Epirubicin
Leucovorin
Esophageal Neoplasms
Combination Drug Therapy
Cisplatin
Fluorouracil
Therapeutics
Adenocarcinoma
Appointments and Schedules
Catheters
Quality of Life
Survival

Keywords

  • Cisplatin
  • Epirubicin
  • Esophageal cancer
  • Leucovorin
  • Oral UFT

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{c7f1d5b5f059414ab154434d7ee7f54c,
title = "Epirubicin, cisplatin, oral UFT, and leucovorin combination chemotherapy in advanced and metastatic esophageal cancer",
abstract = "Background: The purpose of treatment in patients with advanced and metastatic esophageal cancer is to improve symptoms and maintain quality of life. Recently, the regimen including epirubicin, cisplatin, and 5-FU (ECF) has been used with protracted venous infusion (PVI), and has been reported to be an effective treatment for advanced and metastatic csophagastric cancer. However, complications and the inconvenience associated with PVI cannot be justified for the treatment of advanced esophageal cancer. Therefore, we provided treatment with oral UFT and leucovorin instead of 5-FU PVI to improve convenience and catheter related complications. Patients and Methods: Thirty-seven patients with advanced esophageal cancer were admitted between March 2002 and April 2005. The treatment schedule was as follows: epirubicin 50 mg/m2 iv on d 1, cisplatin 60 mg/m2 iv on d 1, oral UFT 300 mg/m2 and leucovorin 75 mg for 21 consecutive days of treatment followed by a 7-d treatment-free interval. Results: The response rate was 45.9{\%} including one complete response (95{\%} CI: 29.8{\%}-62{\%}). The median survival was 13 mo (95{\%} CI: 10-16 mo). Four patients had adenocarcinoma. Interestingly, their response rate was 75{\%} including one complete response. Myelosuppression was the most important toxicity. Other toxicities were tolerable. Conclusion: The combination of epirubicin, cisplatin, UFT, and leucovorin (EPUL) could be another alternative to ECF in patients with advanced esophageal cancer. And this treatment might be more effective in adenocarcinoma of esophageal cancer.",
keywords = "Cisplatin, Epirubicin, Esophageal cancer, Leucovorin, Oral UFT",
author = "Choi, {In Keun} and Seo, {Hee Yun} and Sung, {Hwa Jung} and Park, {Kyong Hwa} and Kim, {Seok Jin} and Oh, {Sang Cheul} and Seo, {Jae Hong} and Choi, {Chul Won} and Kim, {Byung Soo} and Shin, {Sang Won} and Kim, {Yeul Hong} and Kim, {Jun Suk}",
year = "2007",
month = "6",
day = "1",
doi = "10.1007/BF02685900",
language = "English",
volume = "24",
pages = "33--37",
journal = "Medical oncology (Northwood, London, England)",
issn = "1357-0560",
publisher = "Humana Press",
number = "1",

}

TY - JOUR

T1 - Epirubicin, cisplatin, oral UFT, and leucovorin combination chemotherapy in advanced and metastatic esophageal cancer

AU - Choi, In Keun

AU - Seo, Hee Yun

AU - Sung, Hwa Jung

AU - Park, Kyong Hwa

AU - Kim, Seok Jin

AU - Oh, Sang Cheul

AU - Seo, Jae Hong

AU - Choi, Chul Won

AU - Kim, Byung Soo

AU - Shin, Sang Won

AU - Kim, Yeul Hong

AU - Kim, Jun Suk

PY - 2007/6/1

Y1 - 2007/6/1

N2 - Background: The purpose of treatment in patients with advanced and metastatic esophageal cancer is to improve symptoms and maintain quality of life. Recently, the regimen including epirubicin, cisplatin, and 5-FU (ECF) has been used with protracted venous infusion (PVI), and has been reported to be an effective treatment for advanced and metastatic csophagastric cancer. However, complications and the inconvenience associated with PVI cannot be justified for the treatment of advanced esophageal cancer. Therefore, we provided treatment with oral UFT and leucovorin instead of 5-FU PVI to improve convenience and catheter related complications. Patients and Methods: Thirty-seven patients with advanced esophageal cancer were admitted between March 2002 and April 2005. The treatment schedule was as follows: epirubicin 50 mg/m2 iv on d 1, cisplatin 60 mg/m2 iv on d 1, oral UFT 300 mg/m2 and leucovorin 75 mg for 21 consecutive days of treatment followed by a 7-d treatment-free interval. Results: The response rate was 45.9% including one complete response (95% CI: 29.8%-62%). The median survival was 13 mo (95% CI: 10-16 mo). Four patients had adenocarcinoma. Interestingly, their response rate was 75% including one complete response. Myelosuppression was the most important toxicity. Other toxicities were tolerable. Conclusion: The combination of epirubicin, cisplatin, UFT, and leucovorin (EPUL) could be another alternative to ECF in patients with advanced esophageal cancer. And this treatment might be more effective in adenocarcinoma of esophageal cancer.

AB - Background: The purpose of treatment in patients with advanced and metastatic esophageal cancer is to improve symptoms and maintain quality of life. Recently, the regimen including epirubicin, cisplatin, and 5-FU (ECF) has been used with protracted venous infusion (PVI), and has been reported to be an effective treatment for advanced and metastatic csophagastric cancer. However, complications and the inconvenience associated with PVI cannot be justified for the treatment of advanced esophageal cancer. Therefore, we provided treatment with oral UFT and leucovorin instead of 5-FU PVI to improve convenience and catheter related complications. Patients and Methods: Thirty-seven patients with advanced esophageal cancer were admitted between March 2002 and April 2005. The treatment schedule was as follows: epirubicin 50 mg/m2 iv on d 1, cisplatin 60 mg/m2 iv on d 1, oral UFT 300 mg/m2 and leucovorin 75 mg for 21 consecutive days of treatment followed by a 7-d treatment-free interval. Results: The response rate was 45.9% including one complete response (95% CI: 29.8%-62%). The median survival was 13 mo (95% CI: 10-16 mo). Four patients had adenocarcinoma. Interestingly, their response rate was 75% including one complete response. Myelosuppression was the most important toxicity. Other toxicities were tolerable. Conclusion: The combination of epirubicin, cisplatin, UFT, and leucovorin (EPUL) could be another alternative to ECF in patients with advanced esophageal cancer. And this treatment might be more effective in adenocarcinoma of esophageal cancer.

KW - Cisplatin

KW - Epirubicin

KW - Esophageal cancer

KW - Leucovorin

KW - Oral UFT

UR - http://www.scopus.com/inward/record.url?scp=34548715165&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548715165&partnerID=8YFLogxK

U2 - 10.1007/BF02685900

DO - 10.1007/BF02685900

M3 - Article

C2 - 17673809

AN - SCOPUS:34548715165

VL - 24

SP - 33

EP - 37

JO - Medical oncology (Northwood, London, England)

JF - Medical oncology (Northwood, London, England)

SN - 1357-0560

IS - 1

ER -